Investment Highlights

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biotech company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

- Oral presentation of top-line IMPULSE data including invited expert discussion - Poster presentation of new data on lefitolimod as modulator of the tumor microenvironment alone and in combination with immune checkpoint inhibitors in pre-clinical tumor models [more]

Annual Report 2016
Download PDF

 Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

August 10, 2017
Half-Year Report as at June 30, 2017

 

Show complete Corporate Calendar.

September 8 - September 12, 2017

ESMO Annual Meeting, Madrid, Spain


Show complete calendar.

 

 

 

 

ESMO 2017: Positive Feedback to presentations

Press Release
Presentation

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.